AEDs - Free CE Continuing Education online pharmacy, pharmacists

Lacosamide (Vimpat ® )• MOA:– Selective enhancement of sodium channel slow inactivation– Binds to collapsin response mediator protein 2 (CRMP-2)• FDA Approved Indication:– Adjunctive therapy in the treatment of partial-onset seizures in patient with epilepsy aged 17years and older.– Controlled substance (schedule yet to be determined)• Dosage:– Adjunct (partial seizure)• Oral: Initial dose: 50 mg ORALLY twice daily; increase weekly by 100 mg/day given in 2divided doses up to 200 to 400 mg/day• IV: Initial dose: 50 mg IV twice daily; increase weekly by 100 mg/day given in 2 divideddoses up to 200 to 400 mg/day; infuse over 30 to 60 minutes• Dosage Forms:– Tablet: 50 mg (pink), 100 mg (dark yellow), 150 mg (salmon), 200 mg (blue) film-coated tablets– IV Solution: 200 mg/20 mL single-use vial for intravenous use• Pharmacokinetics:– Not affected by food.– Renally eliminated; 300mg/day max for CrCl